2.39
price up icon0.00%   0.00
after-market 시간 외 거래: 2.36 -0.03 -1.26%
loading
전일 마감가:
$2.39
열려 있는:
$2.39
하루 거래량:
47,216
Relative Volume:
0.37
시가총액:
$68.98M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-1.7805
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
-5.53%
1개월 성능:
+0.63%
6개월 성능:
-8.78%
1년 성능:
-39.34%
1일 변동 폭
Value
$2.34
$2.415
1주일 범위
Value
$2.31
$2.63
52주 변동 폭
Value
$1.90
$4.21

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
명칭
Vistagen Therapeutics Inc
Name
전화
650-577-3600
Name
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
직원
48
Name
트위터
@vistagen
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
VTGN's Discussions on Twitter

VTGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VTGN
Vistagen Therapeutics Inc
2.39 73.02M 875.70K -39.57M -33.65M -1.3423
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.27 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.85 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.98 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
484.93 63.90B 14.09B 4.50B 2.96B 39.28

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-12-07 업그레이드 Jefferies Hold → Buy
2023-08-07 업그레이드 Maxim Group Hold → Buy
2022-07-22 다운그레이드 Jefferies Buy → Hold
2022-07-22 다운그레이드 Robert W. Baird Outperform → Neutral
2022-07-22 다운그레이드 William Blair Outperform → Mkt Perform
2021-05-20 개시 Robert W. Baird Outperform
2021-02-18 개시 Jefferies Buy
2021-01-04 업그레이드 William Blair Mkt Perform → Outperform
2018-06-27 개시 Maxim Group Buy
2018-02-08 재확인 Chardan Capital Markets Buy
2017-03-28 개시 Maxim Group Buy
모두보기

Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스

pulisher
Jun 04, 2025

Vistagen Therapeutics (VTGN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN St - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Major Social Anxiety Treatment Breakthrough: Phase 3 Trial Results Coming Q4 2025What to Expect - Stock Titan

Jun 02, 2025
pulisher
May 31, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat

May 31, 2025
pulisher
May 28, 2025

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise

May 28, 2025
pulisher
May 28, 2025

Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 23, 2025

Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan

May 23, 2025
pulisher
May 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat

May 11, 2025
pulisher
May 08, 2025

254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat

May 08, 2025
pulisher
May 06, 2025

Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

May 06, 2025
pulisher
May 05, 2025

Form 8-KCurrent report - ADVFN

May 05, 2025
pulisher
May 04, 2025

Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

May 04, 2025
pulisher
Apr 29, 2025

JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Apr 29, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 24, 2025

JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Apr 24, 2025
pulisher
Apr 17, 2025

Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan

Apr 17, 2025
pulisher
Apr 17, 2025

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace

Apr 17, 2025
pulisher
Apr 08, 2025

Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World

Apr 08, 2025
pulisher
Apr 06, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL - Defense World

Apr 06, 2025
pulisher
Apr 04, 2025

VTGN Stock Touches 52-Week Low at $2.21 Amid Market Challenges - Investing.com UK

Apr 04, 2025
pulisher
Apr 03, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Apr 03, 2025
pulisher
Apr 03, 2025

Mental Disorder Treatment Market Set to Witness Significant - openPR.com

Apr 03, 2025
pulisher
Mar 24, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat

Mar 24, 2025
pulisher
Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR.com

Mar 21, 2025
pulisher
Mar 21, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise

Mar 19, 2025
pulisher
Mar 19, 2025

Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan

Mar 19, 2025
pulisher
Mar 14, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 14, 2025
pulisher
Mar 12, 2025

Vistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. - GuruFocus.com

Mar 12, 2025
pulisher
Mar 08, 2025

VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 04, 2025

Vistagen to Participate in Stifel 2025 Virtual CNS Forum - Business Wire

Mar 04, 2025
pulisher
Mar 02, 2025

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN

Mar 02, 2025
pulisher
Feb 27, 2025

VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results - accessnewswire.com

Feb 27, 2025
pulisher
Feb 27, 2025

VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 25, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat

Feb 25, 2025
pulisher
Feb 20, 2025

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 - ACCESS Newswire

Feb 19, 2025

Vistagen Therapeutics Inc (VTGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
$4.75
price up icon 3.70%
$484.93
price down icon 0.60%
자본화:     |  볼륨(24시간):